COVID-19: A review of therapeutic strategies and vaccine candidates

V Izda, MA Jeffries, AH Sawalha - Clinical Immunology, 2021 - Elsevier
The world is engulfed by one of the most widespread and significant public health crises in
decades as COVID-19 has become among the leading causes of death internationally. The …

Natural history of COVID-19 and therapeutic options

P Gautret, M Million, PA Jarrot… - Expert review of …, 2020 - Taylor & Francis
Introduction: COVID-19 presents benign forms in young patients who frequently present with
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …

[HTML][HTML] RETRACTED: Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: An estimate

A Pradelle, S Mainbourg, S Provencher, E Massy… - 2024 - Elsevier
Following publication, the Journal was made aware of readers' debate about this article. The
Journal received a number of Letters to the Editor and correspondence from readers. The …

Coronavirus disease 2019 as cause of viral sepsis: a systematic review and meta-analysis

E Karakike, EJ Giamarellos-Bourboulis… - Critical care …, 2021 - journals.lww.com
Objective: Coronavirus disease 2019 is a heterogeneous disease most frequently causing
respiratory tract infection, which can induce respiratory failure and multiple organ …

Persistent SARS-2 infections contribute to long COVID-19

JJL Jacobs - Medical hypotheses, 2021 - Elsevier
COVID-19 is a serious disease that has infected more than 40 million people. Beside
significant mortality, the SARS-CoV-2 infection causes considerable and sustained …

[HTML][HTML] Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression

BJ Langford, M So, V Leung, S Raybardhan… - Clinical Microbiology …, 2022 - Elsevier
Background The prevalence of bacterial infection in patients with COVID-19 is low, however,
empiric antibiotic use is high. Risk stratification may be needed to minimize unnecessary …

[HTML][HTML] Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support

K Crothers, R DeFaccio, J Tate… - European …, 2022 - publications.ersnet.org
Background Dexamethasone decreases mortality in coronavirus disease 2019 (COVID-19)
patients on intensive respiratory support (IRS) but is of uncertain benefit if less severely ill …

Comparison of a target trial emulation framework vs Cox regression to estimate the association of corticosteroids with COVID-19 mortality

KL Hoffman, EJ Schenck, MJ Satlin… - JAMA Network …, 2022 - jamanetwork.com
Importance Communication and adoption of modern study design and analytical techniques
is of high importance for the improvement of clinical research from observational data …

Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial

N Toroghi, L Abbasian, A Nourian… - Pharmacological …, 2022 - Springer
Background and objectives Corticosteroids are commonly used in the treatment of
hospitalized patients with COVID-19. The goals of the present study were to compare the …

[HTML][HTML] Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет

ЕЛ Насонов - Научно-практическая ревматология, 2021 - cyberleninka.ru
Пандемия коронавирусной болезни 2019 (coronavirus disease, COVID-19),
этиологически связанной с вирусом SARS-CoV-2 (severe acute respiratory syndrome …